Abstract library

27 results for "Christ".
#1098 177Lu Dotatate vs Sequential 177Lu Dotatate and 90Y Dotatate: Treatment Outcomes for PRRT Patients at the Christie - A Clinical Audit
Introduction: The traditional treatment regime of somatostatin receptor positive NETs by molecular radiotherapy was based on single radionuclides (e.g. 90Y Dotatate or 177Lu Dotatate), delivered as multiple cycles to allow normal tissue recovery. However a newer practice of alternating tcycles of 177Lu and Y90 Dotatate was implemented at the Christie following introduction of this regime in some European centres. Subsequent follow up studies have indicated that longer overall survival and reduced loss of kidney function is found in patient cohorts treated with combined 177Lu and 90Y regimes to either 177Lu or 90Y alone.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Emma Page
Authors: Page E, Tipping J, Birch E, Hamilton D, ...
Keywords: PRRT, Toxicity, Audit, RM Dose
#1002 Retrospective Study of MIBG Therapy for Phaeochromocytoma (PH) and Paraganglioma (PG): The Christie Experience
Introduction: PH & PG are rare neuroendocrine tumors treated with MIBG but protocols are not standardized and reported results are variable.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: Dr Zena Salih
Keywords: mibg
#1345 To Evaluate How the Outcome of Neuroendocrine Tumour (NET) Multidisciplinary Team (MDT) Meeting Decisions Are Conveyed to Patients at a ENETS Centre of Excellence (The Christie) and How This Service Can Be Further Improved
Introduction: It is recommended that people with cancer should be managed by an MDT and the outcomes should be communicated in a “timely manner”. However, it does not specify when this should be done, or by whom.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: Christina Rigby
Authors: Rigby C, Mansoor W, Valle J, Hubner R, ...
#125 Ectopic hormone secreting phaeochromocytoma: A francophone observational study
Introduction: Ectopic hormone-secreting phaeochromocytomas are rare and only small reports of 1-2 cases exist in the literature. In the past, this condition has been linked with increased malignancy, familial syndromes and ACTH secretion.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Bruno Carnaille
#170 Swiss Neuroendocrine Tumor (SwissNET) registry: Results after 30 Months
Introduction: The Swiss registry for NETs (SwissNET) was established in 2008 to improve epidemiological data on NET patients in Switzerland. Here the results after 30 months of follow-up are presented.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Christoph Stettler
#397 Swiss Neuroendocrine Tumor (SwissNET) Registry: Update After Three Years
Introduction: To improve epidemiological data on patients with neuroendocrine tumors (NETs) in Switzerland, the Swiss registry for NETs (SwissNET) was established in 2008. Here we present the current state of the registry in 2011.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Professor Christoph Stettler
#403 Insulinomas in Children
Introduction: Insulinomas are extremely rare tumors in children and an uncommon first manifestation of MEN1 syndrome. Insulinomas are usually benign tumors with only a few reports of malignant cases in children.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Maria Melikian
Keywords: MEN-1
#477 Glucagon-Like Peptide 1 Receptor (GLP-1R) Imaging for the Preoperative Localization of Benign Insulinomas in 30 Patients
Introduction: Biochemical diagnosis of endogenous hyperinsulinemic hypoglycemia is straightforward. Surgical removal of an insulinoma is hampered by difficulties to localize it using conventional radiological procedures. In vitro data suggest that human insulinoma cells exhibit a high density of GLP-1R. 111In-exendin-4 is an 111In labeled GLP-1R agonist that binds with high affinity to GLP-1R and may be helpful in localizing insulinomas.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD, PhD Emanuel Christ
Authors: Christ E, Forrer F, Wild D, Clerici T, ...
#823 Association Between Tumor Expression of VEGFA, VEGFR1 (FLT1), VEGFR2 (KDR), and Clinical Outcomes in Neuroendocrine Tumors
Introduction: Clinical studies have suggested efficacy of VEGF pathway inhibitors in the treatment of advanced neuroendocrine tumors (NETs).
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr. Zhirong Qian
#923 A Case Report of a Pancreatic Neuroendocrine Tumor (pNET) With High Levels of 5-HIAA in Urine
Introduction: A 79-year-old man presented with weakness and weight loss. Clinical examination revealed a palpable liver and CT scan a mass in the head of pancreas and multiple liver lesions.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Dr Nikolaos Tsoukalas
Keywords: 5-HIAA, pancreas, pNET
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.